Natera

Yahoo Finance • 3 months ago

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera’s ability to predict chemotherapy benefit Shows a 50% reduction in risk of death for Signatera-positive patients when treated with ACT... Full story

Yahoo Finance • 4 months ago

Trade Overview: Where Gurus Found Value in the 2nd Quarter

With the latest round of 13F filings released over the past month, investors and market watchers alike are interested in seeing where the major hedge fund managers are finding value opportunities. Background Managers with more than $100... Full story

Yahoo Finance • 4 months ago

Natera, Inc. (NTRA): Among Morgan Stanley’s Highest Conviction Stocks

We recently compiled a list of the Morgan Stanley's Highest Conviction Stocks: Top 20 Stocks To Buy.In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against Morgan Stanley's other high conviction stoc... Full story

Yahoo Finance • 5 months ago

Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference

AUSTIN, Texas, August 06, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference... Full story

Yahoo Finance • 8 months ago

10 Cathie Wood Stocks Insiders are Selling

In this article, we will take a detailed look at the 10 Cathie Wood Stocks Insiders are Selling. For a quick overview of such stocks, read our article5 Cathie Wood Stocks Insiders are Selling. There was a time Cathie Wood talked about her... Full story

Yahoo Finance • 10 months ago

SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)

SEC and Chief Legal Officer Daniel Rabinowitz has sold 2,160 shares of Natera Inc (NASDAQ:NTRA) on March 5, 2024, according to a recent SEC filing. The transaction was reported in a Form 4 document filed with the SEC, which can be accessed... Full story

Yahoo Finance • 10 months ago

Natera Inc Director Herm Rosenman Sells 93,901 Shares

Herm Rosenman, a director at Natera Inc (NASDAQ:NTRA), sold 93,901 shares of the company on February 16, 2024, according to a recent SEC Filing. Natera Inc is a diagnostics company specializing in the field of genetic testing. The company'... Full story

Yahoo Finance • 11 months ago

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.... Full story

Yahoo Finance • 11 months ago

New Study Validates Signatera™ in Endometrial Cancer

Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer AUSTIN, Texas, February 05, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: N... Full story

Yahoo Finance • 11 months ago

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA status in patients with gastric and gas... Full story

Yahoo Finance • 12 months ago

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

2023 revenues are expected to be approximately $20 million above top end of guidance AUSTIN, Texas, January 09, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced prelimin... Full story

Yahoo Finance • last year

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story

Yahoo Finance • last year

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higher AUSTIN, Texas, December 21, 2023--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global l... Full story

Yahoo Finance • last year

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • last year

Insider Sell: CEO Steven Chapman Sells Shares of Natera Inc (NTRA)

In a recent transaction on November 20, 2023, Steven Chapman, the CEO and President of Natera Inc, sold 2,566 shares of the company. This move has caught the attention of investors and analysts, as insider transactions can often provide va... Full story

Yahoo Finance • last year

Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript

Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you for standing by and welcome to the Natera Inc. Q3 Earnings Conference Call. All lines have been placed on mute to prevent any background nois... Full story

Yahoo Finance • last year

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Natera, Inc.’s Directors and Officers for Breach of Fiduciary Duties – NTRA

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Natera, Inc. (“Nate... Full story

Yahoo Finance • last year

Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months AUSTIN, Texas, October 22, 2023--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today a... Full story

Yahoo Finance • last year

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

AUSTIN, Texas, October 19, 2023--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthc... Full story

Yahoo Finance • last year

Stanley Druckenmiller 13F Portfolio: Top 15 Stocks

In this piece, we will take a look at Stanley Druckenmiller's 13F portfolio and its top 15 stock picks. If you want to skip our introduction to the billionaire hedge fund boss and the stock market in general, then take a look at Stanley Dr... Full story